AVCN461 + AVCN504

AVCN461 + AVCN504 is a topical cannabinoid-based drug candidate developed by Avicanna Inc. (AV Cannabis). It is designed to address pain and inflammation, specifically listed in company pipeline documents as 'NSK Pain and Inflammation.' The formulation leverages Avicanna's proprietary scientific platform for the localized delivery of cannabinoids to target tissues. As of early 2024, the candidate has completed observational clinical trials and is in the planning stages for Phase II clinical development. The mechanism of action involves the modulation of pain and inflammatory pathways through the topical application of cannabinoids, which typically interact with the endocannabinoid system (including CB1 and CB2 receptors) to provide analgesic and anti-inflammatory effects.